Kulkarni, M., Hughes, S., Mallia, A., Gibson, V., Young, J., Aggarwal, A., . . . Cook, G. J. R. (2019). The management impact of (68)gallium-tris(hydroxypyridinone) prostate-specific membrane antigen ((68)Ga-THP-PSMA) PET-CT imaging for high-risk and biochemically recurrent prostate cancer. Eur J Nucl Med Mol Imaging.
Citação norma ChicagoKulkarni, Meghana, et al. "The Management Impact of (68)gallium-tris(hydroxypyridinone) Prostate-specific Membrane Antigen ((68)Ga-THP-PSMA) PET-CT Imaging for High-risk and Biochemically Recurrent Prostate Cancer." Eur J Nucl Med Mol Imaging 2019.
Citação norma MLAKulkarni, Meghana, et al. "The Management Impact of (68)gallium-tris(hydroxypyridinone) Prostate-specific Membrane Antigen ((68)Ga-THP-PSMA) PET-CT Imaging for High-risk and Biochemically Recurrent Prostate Cancer." Eur J Nucl Med Mol Imaging 2019.